Skip to main content

Table 2 Patient demographics and sample characteristics

From: Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Age [years]
 Min 37.7  
 P25% 55.7  
 Median 62.46  
 P75% 69.3  
 Max 83.5  
  N %
Menopausal status
 Premenopausal 32 9.9
 Perimenopausal 6 1.9
 Postmenopausal 258 80.1
 NA 26 8.1
Breast-conserving surgery
 Yes 279 86.6
 No 43 13.4
Histological subtype
 Invasive ductal 243 75.5
 Invasive lobular 63 19.6
 Tubular 7 2.2
 Mucinous 5 1.6
 Others 4 1.2
Tumor grading
 G1 83 25.8
 G2 224 69.6
 G3 15 4.7
T-stage
 pT 1a 5 1.6
 pT 1b 72 22.4
 pT 1c 185 57.5
 pT 2 56 17.4
 pT 3 4 1.2
N-stage
 pN 0 278 86.3
 pN 1mic 13 4
 pN 1a 25 7.8
 pN 2a 2 0.6
 pN 3a 3 0.9
 NA 1 0.3